Search Results for “mental health” – Page 13 – media

More walkable neighborhoods have a lower incidence of obesity-related cancers among women

In a recent study published in the journal Environmental Health Perspectives, researchers have found that women living in neighborhoods characterized as walkable, based on factors like population density and accessibility to destinations, have a reduced risk of obesity-related cancers, including postmenopausal breast cancer, as well as multiple myeloma, ovarian, and endometrial cancers. Background Obesity is a growing health concern, with over 40% of adults in the United States being obese or overweight. This condition also significantly increases the risk of various cancers, particularly among women. About 55% of diagnosed cancers in women are linked to obesity, while the figure is approximately 24% for men. Inactivity among women is believed to further exacerbate the risk of obesity-related cancers. Increasing evidence highlights walking as a moderate-intensity physical activity that contributes significantly to recommended exercise levels for maintaining good health. Recent research has focused on how the built environment affects physical activity and, ...
- Source: drugdu
- 124
- October 9, 2023
Parkinson’s UK calls on government to mark World Patient Safety Day

The report outlines ways the government can help patients with Parkinson’s disease Parkinson’s UK has called on the government to take action to help people with Parkinson’s disease (PD) get their medication on time in hospital, as part of its relaunched ‘Get It On Time’ campaign to mark World Patient Safety Day on 17 September. The charity, alongside Diabetes UK, Epilepsy Action, National Aids, Rethink Mental Illness and the Richmond Group, supported by the Royal College of Emergency Medicine and the Royal Pharmaceutical Society, outlined in a joint statement how the government can take action to help patients with PD. PD is a progressive neurological condition which affects an estimated 128,000 people in England. People living with PD can experience severe harm to their health, such as trauma, as a result of not receiving their medication on time while in hospital. The issue also affects patients living with diabetes, epilepsy ...
- Source: drugdu
- 132
- October 1, 2023
New NIH plan outlines HSV research framework with four strategic priorities

In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research. An NIH-wide HSV Working Group developed the plan, informed by feedback from more than 100 representatives of the research and advocacy communities and interested public stakeholders. The plan outlines an HSV research framework with four strategic priorities: improving fundamental knowledge of HSV biology, pathogenesis, and epidemiology; accelerating research to improve HSV diagnosis; improving strategies to treat HSV while seeking a curative therapeutic; and, advancing research to prevent HSV infection. HSV-1 and HSV-2 are among the most common viral infections in the United States. HSV can cause recurring blisters or sores. In severe cases HSV may lead to life-threatening or long-term complications, typically in the central nervous system. There are no licensed preventive HSV vaccines, and there is no cure. Up ...
- Source: drugdu
- 234
- September 21, 2023
Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal

By Tristan Manalac Pictured: Sanofi’s Germany office at night/iStock, Panama7 Sanofi on Monday offloaded 11 brands in its central nervous system portfolio to U.K-based company Pharmanovia, including epilepsy drugs Frisium and Gardenal. The companies did not disclose specific terms of the agreement, but revealed that the medicines span four therapeutic areas—all with ongoing unmet need: psycholeptics, anxiolytics, anti-epileptics and anti-psychotics. Though not all these drugs are approved in every market, they still have “clear synergy” with Pharmanovia’s existing portfolio and will fit well with the company’s “core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need,” CEO James Burt said in a statement. Among the divested drugs are several brands of the benzodiazepine clobazam, including Sentil, Urbanol, Noiafren, Castilium and Frisium. All of these are for the treatment of anxiety in certain patient subgroups; Frisium can also be used as an adjunctive treatment in ...
- Source: drugdu
- 189
- September 21, 2023
UK government allocates £250m for more NHS hospital beds in England

The government has announced a fund of £250m to provide another 5,000 NHS England hospital beds this winter, to relieve pressure on hospitals and reduce waiting times. As part of the NHS Urgent and Emergency Care Recovery Plan, over 30 NHS organisations across England will benefit from the investment in urgent and emergency care services. Over 900 new hospital beds, including 60 intermediate care beds, should be ready by January 2024 to increase capacity on hospital wards and A&E to 100,000. The scheme will also improve assessment spaces and cubicles in A&E. Health and social care secretary, Steve Barclay, said: “Creating additional hospital capacity will support staff to provide the best possible care and treat patients more quickly, helping us to improve waiting times and cut waiting lists – one of the government’s top five priorities.” Trusts including Hull Royal Infirmary, James Cook University Hospital and Worthing Hospital will develop ...
- Source: drugdu
- 114
- August 17, 2023
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression

By Heather McKenzie Pictured: FDA Headquarters/iStock, Grandbrothers In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting therapy zuranolone Friday as the first pill for postpartum depression—but rejected the treatment for major depressive disorder. Zuranolone—to be marketed as Zurzuvae in postpartum depression (PPD) —is only the second treatment for this indication and the first pill that can be taken at home. Prior to Zurzuvae, there was only one FDA-approved treatment for PPD—Sage’s Zulresso (brexanolone)—but as it must be administered intravenously at a hospital, it is out of reach for many women, Fortune Well reported. Zurzuvae also marks a significant change from the current treatment paradigm, which consists of drugs that are longer acting, showing efficacy typically within six to eight weeks, Sage Chief Business Officer Chris Benecchi, told BioSpace in a previous interview. However, the fast-acting pill—jointly developed by Biogen and Sage—can improve symptoms in as ...
- Source: drugdu
- 104
- August 8, 2023
VR Can Alleviate Brain Tumor Patients’ Anxiety During Treatment, Study Finds

AppliedVR teamed up with the National Cancer Institute to study the feasibility of VR to alleviate anxiety in brain tumor patients undergoing imaging scans. The research partners recently announced interim analysis results from their clinical study — they said that not only would VR intervention be a feasible option to reduce patients’ anxiety, but that patients would report high satisfaction levels as well. Patients diagnosed with brain tumors experience notably higher levels of significant distress compared to other solid tumor patients. This heightened distress can be attributed to the disease’s demanding clinical trajectory, as well as its high symptom burden. On top of these challenges, patients with brain tumors face the additional hardship of undergoing frequent neuroimaging assessments to monitor the progress of their disease, leading to what is often referred to as “scanxiety.” This term refers to the anxiety and stress resulting from the anticipation of these medical scans and their potential ...
- Source: drugdu
- 84
- July 25, 2023
EAE Hub Model Reduces Barriers to Early Autism Diagnosis

A new study led by Indiana University School of Medicine researchers shows primary care clinicians who receive specialized training can make accurate autism diagnoses for over 80 percent of young children referred with developmental delays, providing compelling evidence that community-based models of autism evaluation are a potential solution for improving access to this needed service. They recently published their findings in Pediatrics. One in 36 children are now diagnosed with autism, according to the latest 2023 report from the Centers for Disease Control. In many regions of the county, waitlists for autism diagnostic evaluations often exceed a year and families regularly travel long distances to access the limited number of specialists who are qualified to perform these evaluations. Rebecca McNally Keehn (PhD, assistant professor of pediatrics and lead author of the study) said, “The bottleneck families experience in their road to an accurate diagnosis is a public ...
- Source: drugdu
- 134
- July 20, 2023
Racial Discrimination Increases Risk for Childhood Obesity

Children who experience racial discrimination are more likely to later have a higher body mass index (BMI) and larger waistline, according to a new study published in JAMA Network Open. The findings illustrate that racial discrimination may be a risk factor for young people developing obesity—above and beyond other socioeconomic factors such as family income. “Exposure to racial discrimination must be acknowledged as both a social determinant of obesity and a significant contributor to obesity disparities among children and adolescents,” said Adolfo Cuevas, assistant professor of social and behavioral sciences at the NYU School of Global Public Health and the study’s lead author. Childhood obesity is a major public health issue in the U.S., affecting nearly one in five children and teens. Black and Hispanic youth experience even higher rates of obesity, which research shows may stem from factors such as poverty, neighborhood access to healthy foods, and single-parent households. ...
- Source: drugdu
- 107
- July 14, 2023
EMA Concern Stirs over Suicide Risk with Weight Loss GLP-1RA Drugs

The European Medicines Agency (EMA) is reviewing data on the potential effects of high-profile glucagon-like peptide-1 receptor agonists (GLP-1RAs), including Novo Nordisk’s Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide) in causing suicidal thoughts and thoughts of self-harm. The EMA has previously approved these drugs for weight loss and/or as treatments for type 2 diabetes. The EMA investigation comes after the Icelandic Medicines Agency flagged reports of suicidal thoughts and self-injury in patients taking Ozempic and Saxenda. Authorities are so far investigating 150 reports of possible cases of self-injury and suicidal thoughts. Led by the Pharmacovigilance Risk Assessment Committee (PRAC), the EMA evaluation aims to find if these symptoms are linked to the medicines themselves, are unrelated or caused by other underlying factors. The EMA reports that more than 20 million patients in the EU have so far used liraglutide and semaglutide. GLP-1RAs are a rapidly growing ...
- Source: drugdu
- 106
- July 14, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.